Douglas L. Fraker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Douglas L. Fraker has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Joseph Lazar
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
1 shared publication - Ashley M. Fuller
Perelman School of Medicine, University of Pennsylvania 5 Department of Pathology and Laboratory Medicine Philadelphia, PA
1 shared publication - Caitlin B. Finn
Department of Surgery, Center for Surgery and Health Economics, University of Pennsylvania, Pennsylvania
1 shared publication - Carrie Cunningham
Department of Surgery, Mass General Brigham, Boston, USA
1 shared publication - Emre Arslan
The University of Texas MD Anderson Cancer Center 1 Houston, Texas
1 shared publication - Giorgos Constantine Karakousis
University of Pennsylvania 1 Philadelphia, PA
1 shared publication
Latest Publications
- Open Access
- 30 September 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (10)
An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis
We define a subset of macrophages in the tumor microenvironment characterized by high intracellular iron and enrichment of heme and iron metabolism genes. These iron-rich tumor-associated macrophages (iTAMs) supported angiogenesis and immunosuppression in the tumor microenvironment and were conserved between mice and humans. iTAMs comprise two additional subsets based on gene expression profile and location—perivascular (pviTAM) and stromal (stiTAM). We identified the endothelin receptor type B (Ednrb) as a specific marker of iTAMs and found myeloid-specific deletion of Ednrb to reduce tumor growth and vascular density. Further studies identified the transcription factor Bach1 as a repressor of the iTAM transcriptional program, including Ednrb expression. Heme is a known inhibitor of Bach1, and, correspondingly, heme exposure induced Ednrb and iTAM signature genes in macrophages. Thus, iTAMs are a distinct macrophage subset regulated by the transcription factor Bach1 and characterized by Ednrb-mediated immunosuppressive and angiogenic functions.
- 30 September 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (10)
Open AccessAn iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis
We define a subset of macrophages in the tumor microenvironment characterized by high intracellular iron and enrichment of heme and iron metabolism genes. These iron-rich tumor-associated macrophages (iTAMs) supported angiogenesis and immunosuppression in the tumor microenvironment and were conserved between mice and humans. iTAMs comprise two additional subsets based on gene expression profile and location—perivascular (pviTAM) and stromal (stiTAM). We identified the endothelin receptor type B (Ednrb) as a specific marker of iTAMs and found myeloid-specific deletion of Ednrb to reduce tumor growth and vascular density. Further studies identified the transcription factor Bach1 as a repressor of the iTAM transcriptional program, including Ednrb expression. Heme is a known inhibitor of Bach1, and, correspondingly, heme exposure induced Ednrb and iTAM signature genes in macrophages. Thus, iTAMs are a distinct macrophage subset regulated by the transcription factor Bach1 and characterized by Ednrb-mediated immunosuppressive and angiogenic functions.